Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.44 |
| ▸ | TEAD1 | P28347 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26105642 | 1.00 | SLC6A7 (0.46) | SLC6A7TRPV1TEAD1CNR2TRPA1 | |
| SCHEMBL26108174 | 0.86 | HTR1A (0.41) | SLC6A7TRPV1ABL1BCRBTK | |
| SCHEMBL30591869 | 0.86 | HTR1A (0.41) | SLC6A7TRPV1ABL1BCRBTK | |
| SCHEMBL30591592 | 0.82 | SLC6A7 (0.48) | SLC6A7TRPV1TEAD1TRPA1BTK | |
| SCHEMBL26104597 | 0.82 | SLC6A7 (0.48) | SLC6A7TRPV1TEAD1TRPA1BTK | |
| SCHEMBL26496957 | 0.82 | BTK (0.42) | TRPV1BTKHSD11B1 | |
| SCHEMBL26106492 | 0.81 | GPR119 (0.50) | SLC6A7TRPV1TRPA1 | |
| SCHEMBL30591969 | 0.81 | GPR119 (0.50) | SLC6A7TRPV1TRPA1 | |
| SCHEMBL30591917 | 0.81 | MAOB (0.48) | SLC6A7TRPV1CNR2BCHE | |
| SCHEMBL26108257 | 0.81 | MAOB (0.48) | SLC6A7TRPV1CNR2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119403551-A | Small molecule inhibitors of TEA domain family members | 斯克里普斯研究学院 | 2025-02-07 | — | — | CN | claimed |
| EP-4496570-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | The Scripps Research Institute (US) | 2025-01-29 | — | — | EP | claimed |
| WO-2023183768-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-28 | — | — | WO | claimed |
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE | 2025-06-26 | — | — | US | disclosed |
| CN-119403551-A | Small molecule inhibitors of TEA domain family members | 斯克里普斯研究学院 | 2025-02-07 | — | — | CN | disclosed |
| EP-4496570-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | The Scripps Research Institute (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023183768-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | YAP1, TEAD1, TEAD2 | SLC6A7 2221/4885TRPV1 3566/4885TEAD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.